Spotlight on renin: Role of renin in heart failure and therapeutic potential of direct renin inhibition

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 9, Issue 3, 2008, Pages 177-180

  Krum, Henry ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALISKIREN; ANGIOTENSIN; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT; LOSARTAN; PLACEBO; PRORENIN; RAMIPRIL; REMIKIREN; RENIN; RENIN INHIBITOR; SPIRONOLACTONE; VALSARTAN;

ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG SAFETY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERKALEMIA; KIDNEY DYSFUNCTION; MEDICAL RESEARCH; MONOTHERAPY; PATHOPHYSIOLOGY; PLASMA RENIN ACTIVITY; PROGNOSIS; PULMONARY ARTERY OCCLUSION PRESSURE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME; VASCULAR RESISTANCE; ANIMAL; BLOOD; DRUG ANTAGONISM; METABOLISM; REVIEW;

ANIMALS; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; RENIN;

EID: 56749130928     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.1177/1470320308097416     Document Type: Article

References (27)

1. Blaufarb IS, Sonnenblick EH. The renin-angiotensin system in left ventricular remodeling. Am J Cardiol 1996;77:8C-16C.
2. Weir R, McMurray JJ. Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction. Heart 2005;91(suppl 2):ii17-20.
3. Campbell DJ, Aggarwal A, Esler M, Kaye D. Beta-blockers, angiotensin II, and ACE inhibitors in patients with heart failure. Lancet 2001; 358:1609-10.
4. Francis GS, Benedict C, Johnstone DE et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82:1724-9.
5. Brewster UC, Sevaro JF, Perazella MA. The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci 2003;326:15-24.
6. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality CONSENSUS Trial Study Group. Circulation 1990;82:1730-6.
7. Nguyen G. Renin/prorenin receptors. Kidney Int 2006; 69:1503-06.
8. Sakoda M, Ichihara A, Kaneshiro Y et al. (Pro)renin receptor-mediated activation of mitogen-activated protein kinases in human vascular smooth muscle cells. Hypertens Res 2007;30: 1139-46.
9. de Boer RA, Pokharel S, Flesch M et al. Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR(mRen2)27. J Mol Med 2004;82:678-87.
10. Dendorfer A, Dominiak P, Schunkert H. ACE inhibitors and angiotensin II receptor antagonists. Handb Exp Pharmacol 2005;170:407-42.
11. Tang WH, Vagelos RH, Yee YG et al. Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 2002;39(1): 70-8.
12. McMurray JJ, Ostergren J, Swedberg K et al.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-71.
13. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
14. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
15. Lakkis J, Lu WX, Weir MR. RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr Hypertens Rep 2003;5: 408-17.
16. Feldt S, Batenburg WW, Mazak I et al. Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 2008;51:682-8.
17. Feldman DL, Jin L, Xuan H et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008;52:130-6.
18. Mento PF, Maita ME, Murphy WR, Holt WF, Wilkes BM. Comparison of angiotensin converting enzyme and renin inhibition in rats following myocardial infarction. J Cardiovasc Pharmacol 1993; 21:791-6.
19. Pilz B, Shagdarsuren E, Wellner M et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005;46: 569-76.
20. Kiowski W, Beermann J, Rickenbacher P et al. Angiotensinergic versus nonangiotensinergic hemodynamic effects of converting enzyme inhibition in patients with chronic heart failure. Assessment by acute renin and converting enzyme inhibition. Circulation 1994; 90:2748-56.
21. Neuberg GW, Kukin ML, Penn J, Medina N, Yushak M, Packer M. Hemodynamic effects of renin inhibition by enalkiren in chronic congestive heart failure. Am J Cardiol 1991;67:63-6.
22. Waldmeier F, Glaenzel U, Wirz B et al. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos 2007;35:1418-28.
23. Seed A, Gardner R, McMurray J et al. Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. Eur J Heart Fail 2007;9:1120-7.
24. McMurray J, Pitt B, Latini R et al. Effects of the oral direct inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008;1:17-24.
25. Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 2003;24:1735-43.
26. Solomon S, Appelbaum E, Manning WJ et al. Effect of the direct renin inhibitor aliskiren, either alone or in combination with losartan, compared to losartan, on left ventricular mass in patients with hypertension and left ventricular hypertrophy: the Aliskiren Left Ventricular Assessment of Hypertrophy (ALLAY) Trial. Late Breaker presentation at American College of Cardiology 57th Scientific Sessions, 2008.
27. ASPIRE HIGHER clinical program expands to 35,000 patients in 14 trials, the largest cardio-renal outcomes program ever. http://www.novartis.com/ newsroom/mediareleases/en/2008/1228485.shtml June 17 2008.